 Connection
Richard Tobin to CD8-Positive T-Lymphocytes
This is a "connection" page, showing publications Richard Tobin has written about CD8-Positive T-Lymphocytes.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.345 |
|
|
|
-
Palmer WH, Leaton LA, Campos Codo A, Crute B, Roest J, Zhu S, Petersen J, Tobin RP, Hume PS, Stone M, van Bokhoven A, Gerich ME, McCarter MD, Zhu Y, Janssen WJ, Vivian JP, Trowsdale J, Getahun A, Rossjohn J, Cambier J, Loh L, Norman PJ. Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells. Sci Immunol. 2023 06 30; 8(84):eade5343.
Score: 0.153
-
Turner JA, Fredrickson MA, D'Antonio M, Katsnelson E, MacBeth M, Van Gulick R, Chimed TS, McCarter M, D'Alessandro A, Robinson WA, Couts KL, Pelanda R, Klarquist J, Tobin RP, Torres RM. Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity. Nat Commun. 2023 06 03; 14(1):3214.
Score: 0.152
-
Mukherjee N, Katsnelson E, Brunetti TM, Michel K, Couts KL, Lambert KA, Robinson WA, McCarter MD, Norris DA, Tobin RP, Shellman YG. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. Cell Death Dis. 2024 03 08; 15(3):198.
Score: 0.040
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|